

in which

X represents an oxygen atom or a group of formula NZ in which Z represents a hydrogen atom or a (C₁-C₆)alkyl group.

n represents a number 0, 1 or 2, and

R₁, R₂, R₃, R₄ and R₅ each represent, independently of each other, a hydrogen or halogen atom or a trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, phenoxy or phenyl group optionally substituted with a halogen atom or a trifluoromethyl, cyano, hydroxyl, (C₁-C₆)alkyl or (C₁-C₆)alkoxy group, or alternatively R₂ and R₃ together form a group of formula -OCH₂O- or -CH₂CH₂CH₂CH₂-, in the form of a base or of an addition salt with an acid.

3. (amended) A pharmaceutical composition comprising a compound according to Claim 1, combined with an excipient.

Please cancel claim 2.

Please add the following new claims:

4. (added) A compound according to claim 1 wherein X is O, NH or NHCH₃; n is 0 or 1; R₁ is hydrogen, bromo, methyl or methoxy; R₂ is hydrogen, methyl, methoxy, trifluoromethyl, fluoro or chloro; R₃ is chloro, bromo, methyl, methoxy, nitro, fluoro, hydrogen, phenyl, trifluoromethoxy or phenoxy; or R₂ and R₃ together form a group of the formula -OCH₂O- or -CH₂CH₂CH₂CH₂-; R₄ is hydrogen; and R₅ is hydrogen or methoxy; in the form of a base or of an addition salt with an acid.

5. (added) A method for the treatment or prevention of disorders linked to nicotinic receptor dysfunction which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 1.

6. (added) A method for the treatment or prevention of disorders linked to nicotinic receptor dysfunction which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 4.